STICHTING AMSTERDAM UMC

Their core work

Amsterdam UMC is one of the Netherlands' largest academic medical centers, formed from the merger of VUmc and AMC. They conduct translational biomedical research spanning cancer, cardiovascular disease, neurodegenerative disorders, infectious diseases, and mental health — bridging laboratory science with clinical practice. Their strength lies in large-scale clinical trials, advanced medical imaging (MRI and PET), biomarker discovery, and precision medicine approaches. They serve as a major European hub for training the next generation of biomedical researchers through extensive MSCA networks.

What they specialise in

How they've shifted over time

In the early period (2015–2018), Amsterdam UMC focused heavily on personalised medicine, genomics, prevention strategies, and foundational clinical research — building infrastructure for precision health. By the later period (2018–2021), a clear shift emerged toward biomarker discovery, cancer biology, metabolomics, antimicrobial resistance, and inflammatory diseases like atopic dermatitis and psoriasis. The evolution shows a move from broad translational frameworks to highly specific disease-mechanism research powered by multi-omics and data-driven risk stratification.

Amsterdam UMC is moving toward data-intensive, biomarker-driven precision medicine with growing emphasis on multi-morbidity, inflammatory diseases, and antimicrobial resistance — positioning them for next-generation clinical decision support partnerships.

How they like to work

Amsterdam UMC operates as both a strong consortium leader (43 coordinated projects, ~30% of portfolio) and a reliable research partner in large European networks. With 1,129 unique partners across 56 countries, they function as a true network hub rather than a closed-circle collaborator — comfortable anchoring large clinical trials while contributing specialist imaging or biomarker expertise to others' projects. Their heavy participation in MSCA training networks (19 ITN, 6 RISE) shows a deliberate investment in building long-term research relationships through people exchange.

An exceptionally well-connected institution with 1,129 unique consortium partners spanning 56 countries — one of the broadest collaboration networks in European health research. Their partnerships are pan-European with significant global reach, particularly in infectious disease and vaccine development consortia.

What sets them apart

Amsterdam UMC combines the clinical infrastructure of a top-tier university hospital with deep computational and imaging research capabilities — a rare combination that lets them take a project from molecular discovery through clinical validation under one roof. Their dual strength in both coordinating large multi-country trials (GLORIA, SUSTAIN) and contributing niche imaging/biomarker expertise makes them unusually versatile. For consortium builders, they offer credibility, patient access, and an existing network of 1,100+ European partners — a partnership accelerator in any health-related proposal.

Highlights from their portfolio

• GLORIA
  Largest single project at nearly EUR 2M — a major coordinated clinical trial on glucocorticoid treatment strategies, demonstrating their capacity to lead complex interventional studies.
• SEPCELL
  EUR 1.07M project on stem cell therapy for severe sepsis — represents their ability to bridge regenerative medicine with acute care, a high-risk/high-impact research area.
• PANA
  EUR 762K cross-disciplinary project combining nanotechnology with Alzheimer's diagnostics via MRI and PET — showcases their ability to work at the intersection of manufacturing tech and neuroscience.